
  
    
      
        Introduction_NNP
        Activated_NNP protein_NN C_NNP ,_, an_DT endogenous_JJ plasma_NN serine_NN
        protease_NN with_IN antithrombotic_JJ ,_, profibrinolytic_JJ and_CC
        anti-inflammatory_JJ properties_NNS [_NN 1_CD 2_CD 3_CD ]_NN ,_, is_VBZ an_DT important_JJ
        modulator_NN of_IN the_DT host_NN systemic_JJ response_NN to_TO severe_JJ infection_NN
        [_NN 1_CD ]_NN ._. Recently_RB ,_, recombinant_JJ human_JJ activated_VBN protein_NN C_NNP
        (_( drotrecogin_NN alfa_NN [_NN activated_VBN ]_NN )_) was_VBD approved_VBN for_IN the_DT
        treatment_NN of_IN adult_NN patients_NNS with_IN severe_JJ sepsis_NN ._. Regulatory_NNP
        approvals_NNS were_VBD based_VBN on_IN the_DT results_NNS of_IN a_DT single_JJ pivotal_JJ
        phase_NN 3_CD study_NN ,_, which_WDT demonstrated_VBD a_DT statistically_RB
        significantly_RB reduction_NN in_IN 28_CD -_: day_NN all-cause_JJ mortality_NN
        (_( absolute_JJ risk_NN reduction_NN compared_VBN with_IN placebo_NN 6_CD ._. 1_CD %_NN ,_,
        relative_JJ risk_NN reduction_NN 19_CD ._. 4_LS %_NN ;_: 
        P_NN =_SYM 0_CD ._. 005_CD )_) [_NN 4_CD ]_NN ,_, with_IN supporting_VBG
        data_NNS from_IN a_DT single_JJ phase_NN 2_CD study_NN [_NN 5_CD ]_NN ._. Consistent_NNP with_IN
        its_PRP$ antithrombotic_JJ and_CC profibrinolytic_JJ properties_NNS ,_, the_DT
        administration_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) ,_, as_IN compared_VBN
        with_IN placebo_NN ,_, was_VBD associated_VBN with_IN an_DT increase_NN in_IN the_DT
        percentage_NN of_IN patients_NNS experiencing_VBG a_DT serious_JJ bleeding_NN
        complication_NN (_( 3_CD ._. 5_LS %_NN versus_CC 2_CD ._. 0_CD %_NN ;_: 
        P_NN =_SYM 0_CD ._. 06_CD )_) over_IN 28_CD days_NNS in_IN the_DT phase_NN 3_CD
        study_NN [_NN 4_CD ]_NN ._. Bleeding_NNP complications_NNS were_VBD the_DT most_RBS
        important_JJ serious_JJ adverse_JJ events_NNS associated_VBN with_IN the_DT
        administration_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) [_NN 4_CD ]_NN ._.
        A_DT total_NN of_IN 1821_CD adult_NN patients_NNS with_IN severe_JJ sepsis_NN were_VBD
        enrolled_VBN in_IN the_DT randomized_JJ ,_, placebo-controlled_JJ trials_NNS
        supporting_VBG the_DT approval_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) ;_:
        940_CD patients_NNS received_VBD active_JJ treatment_NN and_CC 881_CD patients_NNS
        received_VBD placebo_NN ._. Since_IN completion_NN of_IN those_DT controlled_VBN
        trials_NNS ,_, further_JJ studies_NNS have_VBP been_VBN completed_VBN (_( 
        n_NN =_SYM 2_LS )_) or_CC are_VBP ongoing_JJ (_( 
        n_NN =_SYM 3_LS )_) ,_, in_IN which_WDT an_DT additional_JJ 1846_CD
        patients_NNS have_VBP received_VBN drotrecogin_NN alfa_NN (_( activated_VBN )_) ._.
        Furthermore_RB ,_, up_IN to_TO 12_CD April_NNP 2002_CD ,_, 3991_CD patients_NNS have_VBP
        received_VBN drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN commercial_JJ use_NN
        following_VBG approval_NN in_IN the_DT USA_NNP ._.
        The_DT purpose_NN of_IN this_DT report_NN is_VBZ to_TO provide_VB a_DT comprehensive_JJ
        review_NN of_IN the_DT safety_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) for_IN
        all_DT adult_NN patients_NNS with_IN severe_JJ sepsis_NN enrolled_VBD in_IN clinical_JJ
        trials_NNS (_( completed_VBN and_CC ongoing_JJ )_) since_IN the_DT start_NN of_IN phase_NN 2_CD
        clinical_JJ development_NN and_CC up_IN to_TO 12_CD April_NNP 2002_CD ._. Trials_NNP were_VBD
        grouped_VBN into_IN three_CD categories_NNS :_: controlled_VBN trials_NNS ,_,
        open-label_JJ trials_NNS ,_, and_CC compassionate-use_JJ studies_NNS ._. In_IN
        addition_NN ,_, safety_NN data_NNS are_VBP presented_VBN for_IN patients_NNS who_WP
        received_VBD drotrecogin_NN alfa_NN (_( activated_VBN )_) from_IN spontaneous_JJ
        reports_NNS in_IN commercial_JJ use_NN ._.
      
      
        Patients_NNS and_CC method_NN
        
          Patient_NNP populations_NNS
          Table_NNP 1_CD lists_NNS the_DT seven_CD clinical_JJ studies_NNS that_WDT enrolled_VBD
          adult_NN patients_NNS with_IN severe_JJ sepsis_NN and_CC that_DT were_VBD completed_VBN
          or_CC ongoing_JJ as_IN of_IN 12_CD April_NNP 2002_CD ._. Studies_NNS were_VBD classified_VBN
          as_IN '_POS controlled_VBN '_POS if_IN they_PRP included_VBD a_DT blinded_JJ placebo_NN
          comparison_NN with_IN drotrecogin_NN alfa_NN (_( activated_VBN ;_: Xigris_NNP ®_NN ,_,
          Eli_NNP Lilly_NNP and_CC Company_NN ,_, Indianapolis_NNP ,_, IN_IN ,_, USA_NNP )_) ;_:
          '_POS open-label_JJ '_POS if_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) was_VBD
          administered_VBN in_IN a_DT single_JJ arm_NN study_NN conducted_VBN at_IN
          prospectively_RB identified_VBN and_CC trained_VBN investigative_JJ sites_NNS ;_:
          or_CC '_POS compassionate-use_JJ '_POS if_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
          was_VBD provided_VBN on_IN emergent_NN request_NN to_TO noninvestigator_NN
          clinicians_NNS treating_VBG patients_NNS with_IN severe_JJ sepsis_NN ._.
          All_DT studies_NNS ,_, except_IN F_NN 1_CD K-MC-EVAS_NNP ,_, utilized_JJ inclusion_NN
          and_CC exclusion_NN criteria_NNS similar_JJ to_TO those_DT in_IN the_DT phase_NN 3_CD
          Study_NNP F_NNP 1_CD K-MC-EVAD_NNP (_( Recombinant_NNP Human_NNP Activated_NNP Protein_NNP C_NNP
          Worldwide_NNP Evaluation_NNP in_IN Severe_NNP Sepsis_NNP [_NN PROWESS_NNP ]_NN )_) [_NN 4_CD ]_NN ._.
          Severe_NNP sepsis_NN was_VBD defined_VBN in_IN all_DT protocols_NNS as_IN the_DT
          presence_NN of_IN known_VBN or_CC suspected_VBN infection_NN ,_, the_DT presence_NN of_IN
          a_DT systemic_JJ response_NN to_TO infection_NN (_( as_IN evidenced_VBN by_IN
          alterations_NNS in_IN temperature_NN ,_, heart_NN rate_NN ,_, respiratory_JJ rate_NN ,_,
          and_CC white_JJ blood_NN cell_NN count_NN )_) ,_, and_CC the_DT presence_NN of_IN one_CD or_CC
          more_RBR associated_JJ acute_JJ organ_NN dysfunctions_NNS (_( cardiovascular_JJ ,_,
          respiratory_JJ ,_, renal_JJ ,_, hematologic_JJ ,_, or_CC metabolic_JJ acidemia_NN )_) ._.
          Patients_NNS excluded_VBD from_IN participation_NN included_VBD those_DT at_IN
          high_JJ risk_NN for_IN bleeding_VBG ,_, those_DT with_IN severe_JJ
          thrombocytopenia_NN (_( platelet_NN count_NN ≤_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) ,_, those_DT
          taking_VBG a_DT variety_NN of_IN antiplatelet_NN agents_NNS ,_, and_CC those_DT
          receiving_VBG systemic_JJ heparin_NN anticoagulation_NN ._. Study_NN
          F_NNP 1_CD K-MC-EVAS_NNP required_VBD only_RB the_DT clinical_JJ diagnosis_NN of_IN
          purpura_NN fulminans_NNS and_CC did_VBD not_RB have_VB the_DT presence_NN of_IN
          thrombocytopenia_NN as_IN an_DT exclusion_NN criterion_NN ._.
          Based_VBN on_IN the_DT approved_VBN recommendations_NNS for_IN the_DT USA_NNP ,_,
          patients_NNS receiving_VBG drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN
          commercial_JJ use_NN would_MD have_VB been_VBN expected_VBN to_TO have_VB severe_JJ
          sepsis_NN and_CC have_VBP been_VBN at_IN high_JJ risk_NN for_IN death_NN (_( e_SYM ._. g_SYM ._. as_IN
          assessed_VBN using_VBG the_DT Acute_NNP Physiology_NNP and_CC Chronic_NNP Health_NNP
          Evaluation_NNP [_NN APACHE_NNP ]_NN II_NNP )_) [_NN 6_CD ]_NN ._. The_DT number_NN of_IN patients_NNS
          who_WP received_VBD drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN commercial_JJ
          use_NN was_VBD estimated_VBN from_IN the_DT total_JJ number_NN of_IN courses_NNS of_IN
          therapy_NN sold_VBN in_IN the_DT USA_NNP using_VBG hospital-based_JJ stores_NNS
          information_NN from_IN 21_CD November_NNP 2001_CD until_IN 12_CD April_NNP
          2002_CD ._.
        
        
          Drug_NN administration_NN
          Table_NNP 1_CD lists_NNS details_NNS of_IN drug_NN dose_NN and_CC durations_NNS of_IN
          infusion_NN for_IN each_DT clinical_JJ trial_NN ._. Patients_NNS randomly_RB
          assigned_VBN to_TO placebo_NN in_IN the_DT controlled_VBN clinical_JJ trials_NNS
          received_VBD either_CC saline_NN or_CC 0_CD ._. 1_CD %_NN albumin_NN in_IN saline_NN ._. Based_VBN
          on_IN the_DT approved_VBN recommendations_NNS for_IN the_DT USA_NNP [_NN 6_CD ]_NN ,_,
          patients_NNS receiving_VBG drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN
          commercial_JJ use_NN would_MD have_VB been_VBN expected_VBN to_TO receive_VB an_DT
          infusion_NN rate_NN of_IN 24_CD μg_NN /_NN kg_NN per_IN hour_NN for_IN a_DT total_JJ duration_NN
          of_IN 96_CD hours_NNS ._. Specific_JJ details_NNS regarding_VBG actual_JJ dose_NN and_CC
          duration_NN of_IN administration_NN were_VBD not_RB available_JJ for_IN
          patients_NNS treated_VBN in_IN commercial_JJ use_NN ._.
        
        
          Estimates_NNS of_IN 28_CD -_: day_NN mortality_NN rate_NN
          Mortality_NNP rates_NNS for_IN completed_VBN clinical_JJ trials_NNS were_VBD
          obtained_VBN from_IN validated_JJ clinical_JJ trial_NN databases_NNS ._.
          Estimates_NNS of_IN 28_CD -_: day_NN all-cause_JJ mortality_NN rates_NNS for_IN ongoing_JJ
          clinical_JJ studies_NNS were_VBD obtained_VBN from_IN separate_JJ
          trial-specific_JJ databases_NNS created_VBD using_VBG trial-specific_JJ
          tracking_NN tools_NNS ._. Twenty-eight-day_NNP all-cause_JJ mortality_NN
          (_( i_NNP ._. e_SYM ._. 28_CD days_NNS after_IN the_DT start_NN of_IN infusion_NN )_) was_VBD assessed_VBN
          for_IN all_DT studies_NNS ,_, except_IN study_NN F_NN 1_CD K-MC-EVBC_NNP ,_, in_IN which_WDT 7_CD -_: day_NN
          mortality_NN was_VBD assessed_VBN for_IN a_DT subset_NN of_IN patients_NNS (_( non-_NN US_NNP )_) ._.
          For_IN this_DT subset_NN ,_, the_DT number_NN of_IN additional_JJ deaths_NNS
          occurring_VBG between_IN days_NNS 7_CD and_CC 28_CD was_VBD estimated_VBN using_VBG the_DT
          following_NN method_NN ._. Of_IN the_DT 240_CD adults_NNS in_IN study_NN F_NN 1_CD K-MC-EVBC_NNP ,_,
          28_CD -_: day_NN follow-up_JJ data_NNS were_VBD available_JJ for_IN 168_CD patients_NNS (_( 40_CD
          deaths_NNS )_) and_CC 7_CD -_: day_NN follow_VB up_RP data_NNS were_VBD available_JJ for_IN 72_CD
          patients_NNS (_( 12_CD deaths_NNS )_) ._. It_PRP was_VBD determined_VBN from_IN the_DT result_NN
          of_IN F_NN 1_CD K-MC-EVAD_NNP (_( PROWESS_NNP )_) that_IN the_DT 28_CD -_: day_NN mortality_NN rate_NN
          in_IN 7_CD -_: day_NN survivors_NNS receiving_VBG drotrecogin_NN alfa_NN (_( activated_VBN )_)
          was_VBD 15_CD ._. 2_LS %_NN ._. Therefore_RB ,_, for_IN the_DT subset_NN of_IN 7_CD -_: day_NN survivors_NNS
          in_IN study_NN F_NN 1_CD K-MC-EVBC_NNP ,_, an_DT additional_JJ nine_CD deaths_NNS (_( 15_CD ._. 2_LS %_NN of_IN
          60_CD )_) were_VBD estimated_VBN to_TO have_VB occurred_VBN before_IN study_NN day_NN 28_CD ._.
          Thus_RB ,_, total_JJ 28_CD -_: day_NN mortality_NN in_IN study_NN F_NN 1_CD K-MC-EVBC_NNP was_VBD
          estimated_VBN at_IN (_( 12_CD +_NN 9_CD +_NN 40_CD )_) /_NN 240_CD =_SYM 0_CD ._. 254_CD ._.
          At_IN present_JJ ,_, an_DT estimate_NN of_IN the_DT mortality_NN rate_NN for_IN
          patients_NNS who_WP have_VBP received_VBN drotrecogin_NN alfa_NN (_( activated_VBN )_)
          in_IN commercial_JJ use_NN is_VBZ not_RB available_JJ ._. For_IN the_DT
          placebo-controlled_JJ studies_NNS (_( F_NN 1_CD K-MC-EVAA_NNP and_CC F_NN 1_CD K-MC-EVAD_NNP
          [_NN PROWESS_NNP ]_NN )_) ,_, the_DT cause_NN of_IN death_NN was_VBD adjudicated_JJ by_IN Lilly_NNP
          physicians_NNS ,_, in_IN a_DT blinded_JJ manner_NN ,_, for_IN all_DT patients_NNS from_IN
          death_NN summaries_NNS provided_VBN by_IN the_DT investigators_NNS ._.
        
        
          Serious_NNP bleeding_VBG event_NN rate_NN estimates_NNS
          Bleeding_NNP complications_NNS meeting_VBG the_DT regulatory_JJ
          definition_NN of_IN a_DT serious_JJ adverse_JJ event_NN were_VBD extracted_VBN from_IN
          a_DT validated_JJ pharmacovigilance_NN database_NN ,_, which_WDT included_VBD
          events_NNS reported_VBD in_IN clinical_JJ trials_NNS and_CC in_IN commercial_JJ use_NN ._.
          For_IN all_DT clinical_JJ trials_NNS in_IN this_DT report_NN ,_, bleeding_VBG
          complications_NNS included_VBD ,_, but_CC were_VBD not_RB limited_VBN to_TO ,_, any_DT of_IN
          the_DT following_VBG :_: any_DT intracranial_NN hemorrhage_NN (_( ICH_NNP )_) ;_: any_DT
          life-threatening_JJ bleeding_NN event_NN ;_: requirement_NN for_IN 3_CD units_NNS
          or_CC more_JJR of_IN packed_VBN red_JJ blood_NN cell_NN transfusion_NN per_IN day_NN for_IN
          2_CD consecutive_JJ days_NNS ;_: or_CC meeting_VBG other_JJ criteria_NNS defining_VBG
          serious_JJ adverse_JJ events_NNS ._. For_IN patients_NNS experiencing_VBG ICH_NNP ,_,
          the_DT following_VBG data_NN were_VBD extracted_VBN from_IN the_DT serious_JJ
          adverse_JJ event_NN report_NN :_: type_NN of_IN ICH_NNP ;_: most_RBS recent_JJ platelet_NN
          count_NN ;_: and_CC presence_NN of_IN meningitis_NNS ._.
          The_DT causal_NN relationship_NN of_IN drotrecogin_NN alfa_NN
          (_( activated_VBN )_) to_TO serious_JJ bleeding_NN events_NNS was_VBD assessed_VBN by_IN
          comparison_NN with_IN placebo_NN event_NN rates_NNS for_IN controlled_VBN
          trials_NNS ._. For_IN open-label_JJ and_CC compassionate-use_JJ studies_NNS ,_,
          causal_NN relationship_NN was_VBD assessed_VBN using_VBG investigator_NN
          assignment_NN of_IN causality_NN (_( related_VBN or_CC not_RB related_VBN )_) and_CC by_IN
          comparing_VBG events_NNS that_WDT occurred_VBD during_IN the_DT infusion_NN period_NN
          with_IN events_NNS that_WDT occurred_VBD postinfusion_NN ._. The_DT study_NN drug_NN
          infusion_NN period_NN was_VBD defined_VBN as_IN the_DT actual_JJ duration_NN of_IN
          infusion_NN plus_CC 1_CD calendar_NN day_NN (_( study_NN days_NNS 1_CD -_: 5_LS )_) ._. The_NNP
          '_POS postinfusion_NN period_NN '_'' was_VBD defined_VBN as_IN study_NN days_NNS 6_CD -_: 28_CD ._. All_DT
          serious_JJ bleeding_NN events_NNS were_VBD assessed_VBN as_IN
          '_POS procedure-related_JJ '_POS (_( if_IN associated_VBN with_IN an_DT invasive_JJ
          procedure_NN )_) or_CC '_POS non-procedure-related_JJ '_'' ._.
          Serious_NNP bleeding_VBG events_NNS were_VBD recorded_VBN for_IN up_IN to_TO 28_CD
          days_NNS following_VBG the_DT start_NN of_IN study_NN drug_NN administration_NN for_IN
          all_DT but_CC one_CD study_NN (_( F_NN 1_CD K-MC-EVBC_NNP )_) ._. In_IN study_NN F_NN 1_CD K-MC-EVBC_NNP ,_,
          serious_JJ bleeding_NN events_NNS were_VBD recorded_VBN for_IN up_IN to_TO 28_CD days_NNS ,_,
          except_IN for_IN a_DT subset_NN of_IN patients_NNS (_( 
          n_NN =_SYM 72_CD )_) ._. For_IN this_DT subset_NN ,_, all_DT
          serious_JJ bleeding_NN events_NNS were_VBD recorded_VBN for_IN 7_CD days_NNS
          following_VBG the_DT start_NN of_IN infusion_NN and_CC study_VB drug-related_JJ
          serious_JJ bleeding_NN events_NNS were_VBD recorded_VBN for_IN up_IN to_TO 28_CD
          days_NNS ._.
        
        
          Statistical_NNP analysis_NN
          Because_IN of_IN the_DT lack_NN of_IN final_JJ ,_, validated_JJ baseline_NN data_NNS
          for_IN ongoing_JJ clinical_JJ trials_NNS ,_, comparisons_NNS between_IN clinical_JJ
          trial_NN types_NNS were_VBD avoided_VBN ._. Accordingly_RB ,_, 95_CD %_NN confidence_NN
          intervals_NNS (_( CIs_NNP )_) using_VBG exact_JJ methods_NNS are_VBP reported_VBN for_IN
          event_NN rate_NN estimates_NNS ._. Hypothesis_NNP testing_NN was_VBD not_RB
          performed_VBN as_IN part_NN of_IN the_DT present_JJ study_NN ._. All_DT calculations_NNS
          were_VBD performed_VBN using_VBG SAS_NNP version_NN 8_CD ._. 2_CD software_NN (_( SAS_NNP
          Institute_NNP ,_, Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Twenty-eight-day_NNP all-cause_JJ mortality_NN
          The_DT administration_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) was_VBD
          associated_VBN with_IN a_DT mortality_NN rate_NN in_IN controlled_VBN trials_NNS of_IN
          25_CD ._. 1_LS %_NN (_( 236_CD /_NN 940_CD ;_: 95_CD %_NN CI_NNP 22_CD ._. 4_LS -_: 28_CD ._. 0_CD %_NN )_) ,_, in_IN open-label_JJ studies_NNS
          of_IN 25_CD ._. 2_LS %_NN (_( 398_CD /_NN 1578_CD ;_: 95_CD %_NN CI_NNP 23_CD ._. 1_LS -_: 27_CD ._. 4_LS %_NN )_) ,_, and_CC in_IN
          compassionate-use_JJ studies_NNS of_IN 26_CD ._. 1_LS %_NN (_( 70_CD /_NN 268_CD ;_: 95_CD %_NN CI_NNP
          21_CD ._. 0_CD -_: 31_CD ._. 8_CD %_NN )_) ._. The_DT mortality_NN rate_NN for_IN all_DT patients_NNS treated_VBN
          with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN clinical_JJ trials_NNS was_VBD
          25_CD ._. 3_LS %_NN (_( 704_CD /_NN 2786_CD ;_: 95_CD %_NN CI_NNP 23_CD ._. 7_CD -_: 26_CD ._. 9_CD %_NN )_) ._. The_DT point_NN estimate_NN
          of_IN the_DT mortality_NN rate_NN with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
          for_IN each_DT trial_NN category_NN was_VBD less_JJR than_IN the_DT combined_VBN
          placebo_NN mortality_NN rate_NN of_IN 31_CD ._. 0_CD %_NN (_( 273_CD /_NN 881_CD ;_: 95_CD %_NN CI_NNP
          28_CD ._. 0_CD -_: 34_CD ._. 2_LS %_NN )_) ._. An_DT estimate_NN of_IN the_DT mortality_NN rate_NN for_IN the_DT
          population_NN of_IN patients_NNS who_WP received_VBD drotrecogin_NN alfa_NN
          (_( activated_VBN )_) in_IN commercial_JJ use_NN is_VBZ not_RB available_JJ ._.
          In_IN controlled_VBN clinical_JJ trials_NNS ,_, the_DT leading_VBG causes_NNS of_IN
          death_NN were_VBD multiple_JJ organ_NN failure_NN ,_, refractory_JJ septic_JJ
          shock_NN ,_, and_CC respiratory_JJ failure_NN (_( Table_NNP 2_LS )_) ._. There_EX were_VBD
          numerically_RB fewer_JJR deaths_NNS from_IN refractory_JJ septic_JJ shock_NN and_CC
          respiratory_JJ failure_NN in_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
          treated_VBN patients_NNS than_IN in_IN placebo_NN treated_VBD patients_NNS ._. There_EX
          were_VBD fewer_JJR deaths_NNS from_IN ICH_NNP and_CC stroke_NN combined_VBN in_IN
          drotrecogin_NN alfa_NN (_( activated_VBN )_) treated_VBN patients_NNS than_IN in_IN
          placebo_NN treated_VBD patients_NNS in_IN controlled_VBN trials_NNS (_( Table_NNP
          2_LS )_) ._.
        
        
          Serious_NNP bleeding_VBG events_NNS
          The_DT overall_JJ rate_NN of_IN serious_JJ bleeding_NN events_NNS for_IN all_DT
          patients_NNS treated_VBN with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN all_DT
          clinical_JJ trials_NNS combined_VBN was_VBD 5_CD ._. 3_CD %_NN (_( 148_CD /_NN 2786_CD )_) over_IN the_DT
          28_CD -_: day_NN study_NN period_NN ._. The_DT serious_JJ bleeding_NN event_NN rate_NN
          associated_VBN with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) was_VBD similar_JJ
          across_IN classes_NNS of_IN trials_NNS (_( controlled_VBN ,_, open-label_JJ ,_, and_CC
          compassionate-use_JJ ;_: Table_NNP 3_LS )_) ._.
          The_DT majority_NN of_IN serious_JJ bleeding_NN events_NNS (_( 58_CD /_NN 79_CD )_) that_WDT
          occurred_VBD during_IN the_DT infusion_NN period_NN in_IN patients_NNS in_IN all_DT
          clinical_JJ trials_NNS (_( 2_CD ._. 1_LS %_NN ;_: 58_CD /_NN 2786_CD )_) were_VBD considered_VBN by_IN the_DT
          investigator_NN to_TO be_VB related_VBN to_TO drotrecogin_NN alfa_NN
          (_( activated_VBN )_) ._. When_WRB assessed_VBN ,_, thrombocytopenia_NN (_( platelet_NN
          counts_VBZ ≤_NN 50_CD ,_, 000_CD /_NN mm_NN 3_LS )_) was_VBD frequently_RB present_JJ in_IN
          drotrecogin_NN alfa_NN (_( activated_VBN )_) treated_VBN patients_NNS who_WP
          experienced_VBD a_DT serious_JJ bleeding_NN event_NN during_IN the_DT infusion_NN
          period_NN (_( 22_CD /_NN 53_CD patients_NNS for_IN whom_WP data_NNS were_VBD available_JJ ;_:
          Table_NNP 4_LS )_) ._. Twenty-one_CD serious_JJ bleeding_NN events_NNS ,_, which_WDT
          occurred_VBD during_IN the_DT infusion_NN period_NN (_( 0_CD ._. 8_CD %_NN of_IN all_DT
          patients_NNS ;_: 21_CD /_NN 2786_CD )_) ,_, were_VBD not_RB considered_VBN to_TO be_VB related_VBN to_TO
          drotrecogin_NN alfa_NN (_( activated_VBN )_) ._. This_DT incidence_NN rate_NN (_( 0_CD ._. 8_CD %_NN )_)
          was_VBD similar_JJ to_TO the_DT serious_JJ bleeding_NN event_NN rate_NN observed_VBD
          during_IN the_DT infusion_NN period_NN for_IN placebo_NN treated_VBD patients_NNS
          in_IN controlled_VBN studies_NNS (_( 0_CD ._. 7_CD %_NN ;_: 6_CD /_NN 881_CD )_) ._. In_IN F_NN 1_CD K-MC-EVAD_NNP
          (_( PROWESS_NNP )_) ,_, the_DT incidence_NN of_IN serious_JJ bleeding_NN events_NNS
          during_IN the_DT postinfusion_NN period_NN was_VBD similar_JJ between_IN
          drotrecogin_NN alfa_NN (_( activated_VBN )_) (_( 12_CD /_NN 850_CD )_) and_CC placebo_NN
          patients_NNS (_( 11_CD /_NN 840_CD ;_: both_DT approximately_RB 1_CD %_NN )_) ._. For_IN all_DT
          drotrecogin_NN alfa_NN (_( activated_VBN )_) treated_VBN patients_NNS ,_, only_RB a_DT
          small_JJ minority_NN of_IN serious_JJ bleeding_NN events_NNS that_WDT occurred_VBD
          during_IN the_DT postinfusion_NN period_NN (_( 8_CD /_NN 69_CD events_NNS ;_: 0_CD ._. 3_CD %_NN of_IN all_DT
          patients_NNS )_) were_VBD considered_VBN to_TO be_VB related_VBN to_TO drotrecogin_NN
          alfa_NN (_( activated_VBN )_) ._.
          A_DT relatively_RB high_JJ proportion_NN of_IN all_DT serious_JJ bleeding_NN
          events_NNS was_VBD found_VBN to_TO be_VB related_VBN to_TO invasive_JJ procedures_NNS ,_, as_IN
          shown_VBN in_IN Table_NNP 5_CD ._. In_IN the_DT phase_NN 3_CD trial_NN (_( study_NN F_NN 1_CD K-MC-EVAD_NNP
          [_NN PROWESS_NNP ]_NN )_) ,_, 53_CD ._. 3_LS %_NN (_( 16_CD /_NN 30_CD )_) of_IN serious_JJ bleeding_NN events_NNS in_IN
          drotrecogin_NN alfa_NN (_( activated_VBN )_) treated_VBN patients_NNS and_CC 23_CD ._. 5_LS %_NN
          (_( 4_CD /_NN 17_CD )_) in_IN placebo_NN treated_VBD patients_NNS were_VBD associated_VBN with_IN
          invasive_JJ procedures_NNS during_IN the_DT 28_CD -_: day_NN study_NN period_NN ._. These_DT
          procedures_NNS typically_RB involved_VBD the_DT instrumentation_NN of_IN
          large_JJ blood_NN vessels_NNS or_CC highly_RB vascular_NN organs_NNS ._. The_DT
          incidence_NN of_IN non-procedure-related_JJ serious_JJ bleeding_NN
          events_NNS (_( i_NNP ._. e_SYM ._. spontaneous_JJ bleeding_NN events_NNS )_) was_VBD similar_JJ
          between_IN active_JJ treatment_NN and_CC placebo_NN groups_NNS in_IN that_DT
          trial_NN ._. In_IN all_DT patients_NNS receiving_VBG drotrecogin_NN alfa_NN
          (_( activated_VBN )_) in_IN clinical_JJ trials_NNS ,_, serious_JJ bleeding_NN events_NNS
          associated_VBN with_IN invasive_JJ procedures_NNS accounted_VBD for_IN 39_CD ._. 2_LS %_NN
          (_( 58_CD /_NN 148_CD )_) of_IN the_DT total_JJ number_NN of_IN events_NNS (_( Table_NNP 5_LS )_) ._.
          The_DT incidence_NN of_IN serious_JJ bleeding_NN events_NNS was_VBD highest_JJS
          during_IN the_DT first_JJ day_NN of_IN therapy_NN and_CC decreased_VBD thereafter_RB
          for_IN all_DT drotrecogin_NN alfa_NN (_( activated_VBN )_) treated_VBN patients_NNS ._. Of_IN
          serious_JJ bleeding_NN events_NNS on_IN day_NN 1_CD of_IN therapy_NN ,_, 56_CD %_NN (_( 15_CD /_NN 27_CD )_)
          were_VBD procedure-related_JJ ._. On_IN day_NN 1_CD there_EX were_VBD 12_CD patients_NNS
          with_IN nonprocedure-related_JJ serious_JJ bleeding_NN events_NNS ._.
          Platelet_NNP counts_NNS were_VBD not_RB available_JJ for_IN three_CD of_IN these_DT 12_CD
          patients_NNS ._. Of_IN the_DT remaining_VBG nine_CD patients_NNS ,_, three_CD had_VBD
          severe_JJ thrombocytopenia_NN (_( platelets_NNS ≤_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) and_CC
          three_CD had_VBD an_DT elevated_VBD international_JJ normalized_JJ ratio_NN
          greater_JJR than_IN 2_CD ._. 0_CD ._.
          In_IN commercial_JJ use_NN ,_, 3991_CD patients_NNS received_VBD treatment_NN
          with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN the_DT USA_NNP ._. There_EX have_VBP
          been_VBN 34_CD serious_JJ bleeding_NN events_NNS spontaneously_RB reported_VBD to_TO
          the_DT pharmacovigilance_NN database_NN ,_, for_IN a_DT rate_NN of_IN 0_CD ._. 9_CD %_NN
          (_( 34_CD /_NN 3991_CD )_) ._. If_IN one_CD assumes_VBZ that_IN many_JJ of_IN those_DT patients_NNS had_VBD
          APACHE_NNP II_NNP scores_NNS greater_JJR than_IN 25_CD ,_, then_RB comparison_NN with_IN
          PROWESS_NNP (_( F_NN 1_CD K-MC-EVAD_NNP )_) patients_NNS who_WP had_VBD APACHE_NNP II_NNP scores_NNS
          greater_JJR than_IN 25_CD is_VBZ possible_JJ ._. PROWESS_NNP (_( F_NN 1_CD K-MC-EVAD_NNP )_)
          patients_NNS with_IN APACHE_NNP II_NNP scores_NNS greater_JJR than_IN or_CC equal_JJ to_TO
          25_CD ,_, who_WP received_VBD drotrecogin_NN alfa_NN (_( activated_VBN )_) and_CC
          suffered_VBD serious_JJ bleeding_NN events_NNS during_IN the_DT infusion_NN
          period_NN ,_, amounted_VBD to_TO 9_CD /_NN 414_CD (_( 2_CD ._. 2_LS %_NN )_) and_CC those_DT with_IN scores_NNS
          below_IN 25_CD amounted_VBD to_TO 9_CD /_NN 436_CD (_( 2_CD ._. 1_LS %_NN )_) ._.
          In_IN PROWESS_NNP (_( F_NN 1_CD K-MC-EVAD_NNP )_) ,_, 75_CD %_NN (_( 634_CD /_NN 850_CD )_) of_IN patients_NNS
          who_WP received_VBD drotrecogin_NN alfa_NN (_( activated_VBN )_) and_CC a_DT similar_JJ
          percentage_NN (_( 76_CD %_NN ;_: 637_CD /_NN 840_CD )_) of_IN patients_NNS who_WP received_VBD
          placebo_NN were_VBD exposed_VBN to_TO heparin_NN during_IN the_DT infusion_NN
          period_NN ._. PROWESS_NNP (_( F_NN 1_CD K-MC-EVAD_NNP )_) patients_NNS who_WP had_VBD serious_JJ
          bleeding_NN events_NNS during_IN the_DT infusion_NN period_NN and_CC were_VBD
          exposed_VBN to_TO heparin_NN amounted_VBD to_TO 11_CD /_NN 18_CD (_( 61_CD ._. 1_LS %_NN )_) ._. For_IN
          comparison_NN ,_, 14_CD /_NN 49_CD (_( 28_CD ._. 6_CD %_NN )_) of_IN patients_NNS in_IN open-label_JJ
          trials_NNS and_CC 3_CD /_NN 10_CD (_( 30_CD ._. 0_CD %_NN )_) patients_NNS in_IN compassionate-use_JJ
          trials_NNS who_WP had_VBD serious_JJ bleeding_NN events_NNS during_IN the_DT
          infusion_NN period_NN were_VBD exposed_VBN to_TO heparin_NN ._.
        
        
          Serious_NNP bleeding_VBG events_NNS -_: intracranial_NN hemorrhage_NN
          subset_NN
          In_IN controlled_VBN clinical_JJ trials_NNS ,_, two_CD patients_NNS receiving_VBG
          drotrecogin_NN alfa_NN (_( activated_VBN ;_: 0_CD ._. 2_CD %_NN ;_: 2_CD /_NN 940_CD )_) and_CC one_CD patient_NN
          receiving_VBG placebo_NN (_( 0_CD ._. 1_LS %_NN ;_: 1_CD /_NN 881_CD )_) experienced_VBN ICH_NNP (_( all_DT
          reported_VBD as_IN parenchymal_NN )_) ._. Both_DT events_NNS in_IN the_DT drotrecogin_NN
          alfa_NN (_( activated_VBN )_) group_NN occurred_VBD during_IN the_DT study_NN drug_NN
          infusion_NN period_NN and_CC were_VBD associated_VBN with_IN severe_JJ
          thrombocytopenia_NN (_( platelet_NN count_NN ≤_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) ._. All_DT
          three_CD events_NNS were_VBD associated_VBN with_IN a_DT fatal_JJ outcome_NN ._. In_IN
          open-label_JJ studies_NNS ,_, 11_CD and_CC 10_CD patients_NNS receiving_VBG
          drotrecogin_NN alfa_NN (_( activated_VBN )_) experienced_VBN ICH_NNP during_IN the_DT
          infusion_NN period_NN (_( 0_CD ._. 7_CD %_NN )_) and_CC postinfusion_NN period_NN (_( 0_CD ._. 6_CD %_NN )_) ,_,
          respectively_RB ._. Three_CD and_CC six_CD patients_NNS receiving_VBG
          drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN compassionate-use_JJ studies_NNS
          experienced_VBD ICH_NNP during_IN the_DT infusion_NN period_NN (_( 1_CD ._. 1_LS %_NN )_) and_CC
          postinfusion_NN period_NN (_( 2_CD ._. 2_LS %_NN )_) ,_, respectively_RB ._.
          For_IN all_DT patients_NNS receiving_VBG drotrecogin_NN alfa_NN
          (_( activated_VBN )_) in_IN clinical_JJ trials_NNS ,_, the_DT ICH_NNP rate_NN was_VBD 0_CD ._. 6_CD %_NN
          (_( 16_CD /_NN 2786_CD )_) during_IN the_DT study_NN drug_NN infusion_NN period_NN and_CC 0_CD ._. 6_CD %_NN
          (_( 16_CD /_NN 2786_CD )_) during_IN the_DT postinfusion_NN period_NN ._. The_DT overall_JJ
          28_CD -_: day_NN ICH_NNP event_NN rate_NN was_VBD 1_CD ._. 1_CD %_NN (_( 32_CD /_NN 2786_CD )_) ._.
          Parenchymal_NNP hemorrhage_NN (_( 
          n_NN =_SYM 14_CD )_) was_VBD the_DT most_RBS common_JJ site_NN of_IN
          ICH_NNP event_NN during_IN the_DT infusion_NN period_NN (_( Table_NNP 6_CD )_) ._. Nine_CD ICH_NNP
          events_NNS that_WDT occurred_VBD during_IN the_DT infusion_NN period_NN were_VBD
          fatal_JJ ,_, of_IN which_WDT seven_CD were_VBD considered_VBN related_VBN to_TO
          drotrecogin_NN alfa_NN (_( activated_VBN )_) (_( Table_NNP 7_CD )_) ._. Five_CD of_IN these_DT
          seven_CD events_NNS ,_, which_WDT were_VBD considered_VBN to_TO be_VB related_VBN to_TO
          drotrecogin_NN alfa_NN (_( activated_VBN )_) ,_, were_VBD associated_VBN with_IN
          thrombocytopenia_NN (_( platelets_NNS ≤_NN 50_CD ,_, 000_CD /_NN mm_NN 3_CD ;_: range_NN
          17_CD ,_, 000_CD -_: 49_CD ,_, 000_CD /_NN mm_NN 3_LS )_) ._. Meningitis_NNP was_VBD present_JJ in_IN two_CD of_IN
          those_DT five_CD events_NNS ,_, and_CC severe_JJ thrombocytopenia_NN (_( platelets_NNS
          ≤_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) was_VBD present_JJ in_IN four_CD of_IN those_DT five_CD events_NNS ._.
          Ten_CD of_IN the_DT 16_CD events_NNS (_( 62_CD ._. 5_LS %_NN )_) had_VBD one_CD or_CC both_DT potential_JJ
          risk_NN factors_NNS (_( Table_NNP 8_CD )_) ._. Eight_CD fatal_JJ ICH_NNP events_NNS occurred_VBD
          during_IN the_DT postinfusion_NN period_NN ,_, of_IN which_WDT only_RB one_CD was_VBD
          considered_VBN related_VBN to_TO drotrecogin_NN alfa_NN (_( activated_VBN )_) ._. The_DT
          other_JJ seven_CD fatal_JJ ICH_NNP events_NNS considered_VBN not_RB related_VBN to_TO
          drotrecogin_NN alfa_NN (_( activated_VBN )_) occurred_VBD between_IN study_NN days_NNS
          8_CD and_CC 28_CD -_: well_RB after_IN the_DT infusion_NN period_NN ._.
          In_IN commercial_JJ use_NN ,_, 0_CD ._. 2_CD %_NN (_( 8_CD /_NN 3991_CD )_) patients_NNS receiving_VBG
          drotrecogin_NN alfa_NN (_( activated_VBN )_) were_VBD reported_VBN to_TO have_VB
          experienced_VBN an_DT ICH_NNP ._.
        
        
          Non-_NNP ICH_NNP serious_JJ bleeding_NN events_NNS associated_VBN with_IN
          fatal_JJ outcome_NN
          In_IN controlled_VBN clinical_JJ trials_NNS ,_, four_CD drotrecogin_NN alfa_NN
          (_( activated_VBN )_) patients_NNS and_CC one_CD placebo_NN patient_NN experienced_VBD
          non-_NN ICH_NNP serious_JJ bleeding_NN events_NNS associated_VBN with_IN a_DT fatal_JJ
          outcome_NN based_VBN on_IN adjudicated_JJ cause_NN of_IN death_NN ._. Fatal_NNP
          non-_NN ICH_NNP serious_JJ bleeding_NN events_NNS that_WDT were_VBD reported_VBN as_IN
          serious_JJ adverse_JJ events_NNS for_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
          patients_NNS in_IN all_DT clinical_JJ trials_NNS combined_VBN are_VBP presented_VBN in_IN
          Table_NNP 8_CD ._. Three_CD patients_NNS experienced_VBD non-_NN ICH_NNP serious_JJ
          bleeding_NN events_NNS associated_VBN with_IN a_DT fatal_JJ outcome_NN ._. All_DT
          three_CD events_NNS occurred_VBD during_IN the_DT infusion_NN period_NN and_CC all_DT
          were_VBD considered_VBN related_VBN to_TO drotrecogin_NN alfa_NN (_( activated_VBN )_) ._.
          One_CD of_IN these_DT involved_VBN thrombocytopenia_NN (_( platelets_NNS
          19_CD ,_, 000_CD /_NN mm_NN 3_LS )_) with_IN severe_JJ coagulopathy_NN (_( partial_JJ
          thromboplastin_NN time_NN ≥_NN 150_CD s_VBZ )_) ._.
        
      
      
        Discussion_NNP
        The_DT observed_VBN mortality_NN rates_NNS for_IN patients_NNS receiving_VBG
        drotrecogin_NN alfa_NN (_( activated_VBN )_) were_VBD consistent_JJ across_IN
        controlled_VBN ,_, open-label_JJ and_CC compassionate-use_JJ trials_NNS ,_,
        ranging_VBG from_IN 25_CD ._. 1_LS %_NN to_TO 26_CD ._. 1_LS %_NN ._. These_DT results_NNS are_VBP similar_JJ to_TO ,_,
        and_CC supportive_JJ of_IN ,_, the_DT observed_VBN mortality_NN rate_NN of_IN 24_CD ._. 7_CD %_NN
        associated_VBN with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) use_NN reported_VBD
        in_IN the_DT pivotal_JJ ,_, phase_NN 3_CD trial_NN F_NN 1_CD K-MC-EVAD_NNP (_( PROWESS_NNP )_) [_NN 4_CD ]_NN ._.
        These_DT mortality_NN rates_NNS are_VBP lower_JJR than_IN recent_JJ mortality_NN rate_NN
        estimates_NNS for_IN severe_JJ sepsis_NN ,_, which_WDT ranged_VBD between_IN 30_CD %_NN and_CC
        50_CD %_NN [_NN 7_CD ]_NN and_CC lower_JJR than_IN the_DT combined_VBN placebo_NN rate_NN from_IN
        controlled_VBN clinical_JJ trials_NNS of_IN 31_CD ._. 0_CD %_NN ._. The_DT consistency_NN of_IN
        treatment_NN effects_NNS in_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) patients_NNS
        might_MD have_VB been_VBN expected_VBN given_VBN that_IN ,_, for_IN the_DT most_JJS part_NN ,_,
        inclusion_NN and_CC exclusion_NN criteria_NNS were_VBD similar_JJ across_IN
        trials_NNS ._.
        The_DT survival_NN benefit_NN associated_VBN with_IN drotrecogin_NN alfa_NN
        (_( activated_VBN )_) appears_VBZ to_TO be_VB related_VBN to_TO a_DT reduction_NN in_IN the_DT
        number_NN of_IN deaths_NNS from_IN refractory_JJ septic_JJ shock_NN and_CC
        respiratory_JJ failure_NN ._. These_DT observations_NNS are_VBP consistent_JJ with_IN
        the_DT observed_VBN more_RBR rapid_JJ improvement_NN in_IN cardiovascular_JJ and_CC
        respiratory_JJ function_NN for_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
        patients_NNS as_IN compared_VBN with_IN placebo_NN patients_NNS in_IN study_NN
        F_NN 1_CD K-MC-EVAD_NNP (_( PROWESS_NNP )_) [_NN 8_CD ]_NN ._.
        Consistent_NNP with_IN its_PRP$ antithrombotic_JJ and_CC profibrinolytic_JJ
        properties_NNS ,_, drotrecogin_NN alfa_NN (_( activated_VBN )_) increased_VBD the_DT risk_NN
        for_IN serious_JJ bleeding_NN ._. The_DT overall_JJ serious_JJ bleeding_NN event_NN
        rate_NN (_( 5_CD ._. 3_LS %_NN )_) includes_VBZ compassionate-use_JJ trials_NNS ,_, in_IN which_WDT
        investigators_NNS had_VBD limited_JJ experience_NN using_VBG drotrecogin_NN alfa_NN
        (_( activated_VBN )_) ._. The_DT percentage_NN of_IN patients_NNS experiencing_VBG an_DT
        event_NN probably_RB related_VBD to_TO drotrecogin_NN alfa_NN (_( activated_VBN )_)
        appears_VBZ to_TO range_VB between_IN 2_CD ._. 1_CD %_NN and_CC 2_CD ._. 8_CD %_NN ,_, as_IN assessed_VBN by_IN the_DT
        investigator_NN or_CC by_IN whether_IN the_DT event_NN occurred_VBD during_IN the_DT
        infusion_NN period_NN ,_, respectively_RB ._. Approximately_RB 2_CD ._. 0_CD %_NN of_IN
        placebo_NN patients_NNS enrolled_VBD in_IN controlled_VBN trials_NNS experienced_VBD
        a_DT serious_JJ bleeding_NN event_NN over_IN the_DT 28_CD -_: day_NN period_NN ._. Neither_DT
        APACHE_NNP II_NNP score_NN (_( <_NN 25_CD or_CC ≥_NN 25_CD )_) nor_CC concomitant_NN heparin_NN
        use_NN appear_VBP to_TO alter_VB serious_JJ bleeding_NN event_NN rates_NNS associated_VBN
        with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) substantially_RB ._.
        Underreporting_NNP of_IN baseline_NN heparin_NN exposure_NN in_IN the_DT
        open-label_JJ and_CC compassionate-use_JJ trials_NNS is_VBZ likely_JJ ,_, given_VBN
        that_IN medication_NN listings_NNS for_IN the_DT safety_NN database_NN were_VBD only_RB
        collected_VBN on_IN the_DT day_NN of_IN the_DT event_NN ._.
        Serious_NNP bleeding_VBG event_NN rates_NNS for_IN both_DT active_JJ treatment_NN
        and_CC placebo_NN patients_NNS enrolled_VBD in_IN clinical_JJ trials_NNS of_IN
        drotrecogin_NN alfa_NN (_( activated_VBN )_) probably_RB underestimate_NN the_DT
        bleeding_VBG risk_NN for_IN all_DT patients_NNS with_IN severe_JJ sepsis_NN ._. In_IN these_DT
        trials_NNS ,_, patients_NNS at_IN increased_VBN risk_NN for_IN bleeding_VBG (_( e_SYM ._. g_SYM ._. some_DT
        patients_NNS with_IN multiple_JJ trauma_NN )_) or_CC patients_NNS with_IN severe_JJ
        thrombocytopenia_NN (_( i_NNP ._. e_SYM ._. platelet_NN count_NN ≤_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) were_VBD
        excluded_VBN from_IN participation_NN ._. Clinical_NNP trials_NNS of_IN treatment_NN
        of_IN severe_JJ sepsis_NN with_IN other_JJ novel_NN therapeutics_NNS that_WDT have_VBP
        antithrombotic_JJ properties_NNS also_RB excluded_VBD a_DT similar_JJ patient_NN
        population_NN ._. Estimates_NNS of_IN serious_JJ bleeding_NN complications_NNS in_IN
        these_DT latter_JJ trials_NNS ranged_VBD between_IN 6_CD ._. 0_CD %_NN [_NN 9_CD ]_NN and_CC 12_CD ._. 8_CD %_NN [_NN
        10_CD ]_NN for_IN placebo_NN treated_VBD patients_NNS ._. Exclusion_NNP criteria_NNS
        related_VBN to_TO bleeding_VBG risk_NN similar_JJ to_TO those_DT used_VBN in_IN all_DT of_IN
        these_DT trials_NNS should_MD be_VB employed_VBN in_IN developing_VBG guidelines_NNS
        for_IN the_DT use_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) ._.
        Severe_NNP thrombocytopenia_NN is_VBZ included_VBN as_IN a_NNP '_POS warning_NN '_'' in_IN
        the_DT US_NNP Package_NNP Insert_NNP and_CC as_IN a_NNP '_POS contraindication_NN '_'' in_IN the_DT
        European_NNP Summary_NNP of_IN Product_NNP Characteristics_NNP ._. In_IN the_DT former_JJ
        instance_NN ,_, the_DT recommendation_NN is_VBZ for_IN physicians_NNS to_TO weigh_VB
        potential_JJ benefit_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) against_IN a_DT
        potentially_RB increased_VBN risk_NN associated_VBN with_IN its_PRP$ use_NN ._. In_IN the_DT
        European_NNP Summary_NNP of_IN Product_NNP Characteristics_NNP ,_, the_DT
        recommendation_NN is_VBZ that_IN physicians_NNS not_RB administer_VB
        drotrecogin_NN alfa_NN (_( activated_VBN )_) to_TO patients_NNS with_IN platelet_NN
        counts_NNS of_IN 30_CD ,_, 000_CD /_NN mm_NN 3_CD or_CC less_JJR ._. Indeed_RB ,_, serious_JJ bleeding_NN
        events_NNS in_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) patients_NNS appear_VBP to_TO
        be_VB associated_VBN with_IN severe_JJ thrombocytopenia_NN ,_, suggesting_VBG that_IN
        this_DT characteristic_NN may_MD be_VB a_DT risk_NN factor_NN for_IN bleeding_VBG
        complications_NNS ._. Therefore_RB ,_, maintaining_VBG a_DT platelet_NN count_NN
        above_IN 30_CD ,_, 000_CD /_NN mm_NN 3_CD and_CC discontinuing_VBG the_DT drotrecogin_NN alfa_NN
        (_( activated_VBN )_) infusion_NN if_IN the_DT platelet_NN count_NN falls_VBZ below_IN this_DT
        level_NN are_VBP reasonable_JJ recommendations_NNS to_TO guide_VB its_PRP$ use_NN ._.
        A_DT large_JJ percentage_NN of_IN bleeding_VBG events_NNS associated_VBN with_IN
        drotrecogin_NN alfa_NN (_( activated_VBN )_) were_VBD also_RB related_VBN to_TO
        procedures_NNS performed_VBN either_CC before_IN or_CC during_IN the_DT infusion_NN
        period_NN ._. The_DT types_NNS of_IN procedures_NNS associated_VBN with_IN bleeding_VBG
        complications_NNS were_VBD frequently_RB those_DT in_IN which_WDT adequate_JJ
        control_NN of_IN bleeding_VBG vessels_NNS could_MD not_RB be_VB obtained_VBN ._. In_IN
        controlled_VBN trials_NNS ,_, the_DT percentage_NN of_IN patients_NNS experiencing_VBG
        non-procedure-related_JJ bleeding_NN complications_NNS was_VBD similar_JJ
        between_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) and_CC placebo_NN patients_NNS ._.
        Therefore_RB ,_, limiting_VBG invasive_JJ procedures_NNS before_IN and_CC during_IN
        infusion_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) ,_, as_RB well_RB as_IN
        minimizing_VBG risks_NNS associated_VBN with_IN procedures_NNS (_( e_SYM ._. g_SYM ._.
        instrumentation_NN of_IN blood_NN vessels_NNS in_IN which_WDT direct_JJ
        compression_NN might_MD be_VB expected_VBN to_TO control_VB bleeding_VBG )_) ,_, could_MD
        improve_VB the_DT safety_NN profile_NN of_IN the_DT drug_NN ._.
        Additionally_RB ,_, approved_VBD product_NN labels_NNS recommend_VBP stopping_VBG
        the_DT drotrecogin_NN alfa_NN (_( activated_VBN )_) infusion_NN 2_CD hours_NNS before_IN
        invasive_JJ procedures_NNS and_CC waiting_VBG 12_CD hours_NNS after_IN major_JJ
        surgical_JJ procedures_NNS to_TO restart_VB the_DT infusion_NN after_IN ensuring_VBG
        adequate_JJ hemostasis_NNS [_NN 6_CD ]_NN ._. The_DT infusion_NN may_MD be_VB restarted_VBN
        immediately_RB after_IN uncomplicated_JJ ,_, less_RBR invasive_JJ procedures_NNS
        after_IN ensuring_VBG adequate_JJ hemostasis_NNS ._. These_DT recommendations_NNS
        are_VBP based_VBN on_IN the_DT observation_NN that_IN the_DT concentration_NN of_IN
        drotrecogin_NN alfa_NN (_( activated_VBN )_) in_IN plasma_NN is_VBZ below_IN the_DT assay_NN
        level_NN of_IN detection_NN in_IN a_DT large_JJ majority_NN of_IN patients_NNS within_IN 2_CD
        hours_NNS of_IN discontinuing_VBG the_DT infusion_NN [_NN 11_CD ]_NN ._.
        The_DT difference_NN between_IN ICH_NNP events_NNS occurring_VBG during_IN the_DT
        infusion_NN period_NN (_( 0_CD ._. 6_CD %_NN )_) or_CC considered_VBN related_VBN to_TO drug_NN ,_, and_CC
        the_DT ICH_NNP event_NN rate_NN in_IN all_DT clinical_JJ trials_NNS combined_VBN (_( 1_CD ._. 1_LS %_NN )_)
        was_VBD similar_JJ to_TO the_DT background_NN rate_NN for_IN ICH_NNP reported_VBD for_IN
        patients_NNS with_IN severe_JJ sepsis_NN ._. In_IN a_DT recent_JJ large_JJ sepsis_NN trial_NN
        of_IN antithrombin_NN III_NNP ,_, 0_CD ._. 4_CD %_NN of_IN placebo_NN treated_VBD patients_NNS
        experienced_VBD ICH_NNP during_IN the_DT study_NN [_NN 10_CD ]_NN ._. Oppenheim-_NNP Eden_NNP 
        et_CC al_NN ._. [_NN 12_CD ]_NN also_RB reported_VBD an_DT ICH_NNP
        event_NN rate_NN of_IN 0_CD ._. 4_CD %_NN for_IN all_DT intensive_JJ care_NN unit_NN patients_NNS who_WP
        did_VBD not_RB have_VB an_DT admitting_VBG diagnosis_NN of_IN stroke_NN or_CC stroke_NN
        syndrome_NN ._. However_RB ,_, all_DT patients_NNS experiencing_VBG ICH_NNP had_VBD a_DT
        diagnosis_NN of_IN severe_JJ sepsis_NN and_CC a_DT platelet_NN count_NN of_IN
        30_CD ,_, 000_CD /_NN mm_NN 3_CD or_CC less_JJR ,_, suggesting_VBG that_IN the_DT event_NN rate_NN for_IN the_DT
        severe_JJ sepsis_NN population_NN overall_NN may_MD exceed_VB 0_CD ._. 4_CD %_NN [_NN 12_CD ]_NN ._.
        In_IN a_DT recently_RB completed_VBN phase_NN 2_CD trial_NN of_IN platelet_NN
        activating_VBG factor-ase_JJ ,_, an_DT ICH_NNP event_NN rate_NN of_IN 2_CD ._. 3_CD %_NN (_( 1_CD /_NN 43_CD )_) was_VBD
        reported_VBN in_IN placebo-treated_JJ sepsis_NN patients_NNS (_( Opal_NNP S_NNP ,_,
        personal_JJ communication_NN )_) ._.
        Approximately_RB 0_CD ._. 4_CD %_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
        patients_NNS experienced_VBD a_DT serious_JJ bleeding_NN event_NN associated_VBN
        with_IN a_DT fatal_JJ outcome_NN that_WDT was_VBD considered_VBN related_VBN to_TO its_PRP$ use_NN
        during_IN the_DT infusion_NN period_NN ._. These_DT events_NNS were_VBD most_RBS
        frequently_RB ICH_NNP events_NNS ._. These_DT data_NNS suggest_VBP that_IN ,_, although_IN
        use_NN of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) reduces_VBZ sepsis-induced_JJ
        mortality_NN ,_, its_PRP$ anticoagulant_NN effects_NNS may_MD increase_VB the_DT risk_NN
        for_IN life-threatening_JJ bleeding_NN complications_NNS ._. Patients_NNS that_WDT
        appear_VBP to_TO be_VB at_IN risk_NN for_IN such_JJ a_DT complication_NN are_NN those_DT with_IN
        severe_JJ coagulopathy_NN (_( i_NNP ._. e_SYM ._. low_JJ platelet_NN counts_VBZ ,_, high_JJ
        international_JJ normalized_JJ ratio_NN )_) ._. Risk_NN for_IN sepsis-related_JJ
        death_NN in_IN these_DT patients_NNS may_MD be_VB greater_JJR than_IN that_DT in_IN the_DT
        overall_JJ population_NN of_IN severe_JJ sepsis_NN patients_NNS with_IN no_DT
        coagulopathy_NN ._.
        In_IN controlled_VBN trials_NNS ,_, although_IN drotrecogin_NN alfa_NN
        (_( activated_VBN )_) treated_VBN patients_NNS experienced_VBD more_RBR
        hemorrhage-related_JJ deaths_NNS ,_, there_EX were_VBD fewer_JJR deaths_NNS from_IN
        stroke_NN in_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) patients_NNS than_IN in_IN
        placebo_NN patients_NNS (_( two_CD versus_CC seven_CD patients_NNS )_) ._. The_DT composite_JJ
        end-point_JJ of_IN any_DT fatal_JJ ICH_NNP and_CC any_DT fatal_JJ stroke_NN favored_VBD
        drotrecogin_NN alfa_NN (_( activated_VBN )_) as_IN compared_VBN with_IN placebo_NN (_( four_CD
        versus_CC eight_CD patients_NNS )_) ._. The_DT number_NN of_IN patients_NNS experiencing_VBG
        any_DT fatal_JJ bleeding_NN event_NN or_CC any_DT fatal_JJ stroke_NN was_VBD similar_JJ
        between_IN the_DT drotrecogin_NN alfa_NN (_( activated_VBN )_) and_CC placebo_NN groups_NNS
        (_( nine_CD versus_CC eight_CD patients_NNS ,_, respectively_RB )_) ._. These_DT data_NNS
        suggest_VBP that_IN the_DT 28_CD -_: day_NN all-cause_JJ mortality_NN rates_NNS reported_VBD
        for_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) represent_VB a_DT composite_JJ
        end-point_JJ of_IN less_RBR sepsis-induced_JJ death_NN ,_, potentially_RB less_RBR
        thrombotic-related_JJ deaths_NNS ,_, as_RB well_RB as_IN any_DT fatal_JJ
        complications_NNS associated_VBN with_IN the_DT use_NN of_IN drotrecogin_NN alfa_NN
        (_( activated_VBN )_) ._.
        The_DT primary_JJ limitation_NN of_IN these_DT analyses_NNS was_VBD the_DT lack_NN of_IN
        placebo_NN treatment_NN groups_NNS for_IN five_CD of_IN the_DT seven_CD studies_NNS
        reported_VBN ,_, and_CC no_DT comparison_NN group_NN for_IN patients_NNS administered_VBN
        drotrecogin_NN alfa_NN (_( activated_VBN )_) under_IN commercial_JJ use_NN ._.
        Additionally_RB ,_, baseline_NN data_NNS describing_VBG the_DT patient_NN
        population_NN was_VBD unavailable_JJ for_IN patients_NNS enrolled_VBD in_IN ongoing_JJ
        trials_NNS or_CC receiving_VBG drotrecogin_NN alfa_NN (_( activated_VBN )_)
        commercially_RB ._. There_EX were_VBD also_RB notable_JJ differences_NNS in_IN the_DT
        inclusion_NN criteria_NNS used_VBN to_TO enroll_VB patients_NNS in_IN the_DT
        compassionate-use_JJ study_NN F_NN 1_CD K-MC-EVAS_NNP (_( i_NNP ._. e_SYM ._. that_DT study_NN
        enrolled_VBD only_RB patients_NNS with_IN purpura_NN fulminans_NNS )_) ._. This_DT
        inclusion_NN criterion_NN may_MD explain_VB ,_, in_IN part_NN ,_, the_DT higher_JJR
        bleeding_VBG rates_NNS seen_VBN in_IN compassionate-use_JJ trials_NNS ._.
      
      
        Conclusion_NNP
        Drotrecogin_NNP alfa_NN (_( activated_VBN )_) significantly_RB reduces_VBZ
        mortality_NN in_IN severe_JJ sepsis_NN ._. The_DT treatment_NN efficacy_NN and_CC
        safety_NN profiles_NNS of_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) have_VBP
        remained_VBN consistent_JJ over_IN multiple_JJ clinical_JJ trials_NNS ._. The_DT only_RB
        significant_JJ serious_JJ adverse_JJ event_NN associated_VBN with_IN
        drotrecogin_NN alfa_NN (_( activated_VBN )_) treatment_NN is_VBZ bleeding_VBG ._.
        Additional_JJ clinical_JJ experience_NN indicates_VBZ that_IN invasive_JJ
        procedures_NNS are_VBP associated_VBN with_IN a_DT substantial_JJ percentage_NN of_IN
        these_DT serious_JJ bleeding_NN events_NNS ._. Severe_NNP thrombocytopenia_NN (_( for_IN
        all_DT serious_JJ bleeding_NN events_NNS )_) and_CC meningitis_NNS (_( for_IN ICH_NNP only_RB )_)
        may_MD be_VB risk_NN factors_NNS for_IN serious_JJ bleeding_NN ._. Mitigating_NNP the_DT
        risk_NN for_IN serious_JJ bleeding_NN by_IN maintaining_VBG adequate_JJ platelets_NNS
        (_( e_SYM ._. g_SYM ._. >_NN 30_CD ,_, 000_CD /_NN mm_NN 3_LS )_) during_IN drotrecogin_NN alfa_NN (_( activated_VBN )_)
        infusion_NN may_MD reduce_VB risk_NN for_IN both_DT bleeding_VBG and_CC ICH_NNP ._.
      
      
        Key_JJ messages_NNS
        •_NN Mortality_NNP rates_NNS in_IN drotrecogin_NN alfa_NN
        (_( activated_VBN )_) -_: treated_VBN patients_NNS remained_VBD consistent_JJ across_IN
        trials_NNS
        •_NN The_DT most_RBS important_JJ serious_JJ adverse_JJ event_NN associated_VBN
        with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) treatment_NN is_VBZ bleeding_VBG
        •_NN Serious_NNP bleeding_VBG events_NNS are_VBP most_RBS frequent_JJ on_IN day_NN 1_CD of_IN
        therapy_NN with_IN drotrecogin_NN alfa_NN (_( activated_VBN )_) and_CC rapidly_RB
        decline_VB on_IN subsequent_JJ days_NNS
        •_NN Serious_NNP bleeding_VBG events_NNS were_VBD frequently_RB
        procedure-associated_JJ
        •_NN ICH_NNP during_IN infusion_NN period_NN of_IN drotrecogin_NN alfa_NN
        (_( activated_VBN )_) was_VBD frequently_RB associated_VBN with_IN severe_JJ
        thrombocytopenia_NN and_CC /_NN or_CC meningitis_NNS
      
      
        Competing_VBG interests_NNS
        Gordon_NNP R_NNP Bernard_NNP received_VBD grant_VB support_NN from_IN Eli_NNP Lilly_NNP
        and_CC Company_NN and_CC serves_VBZ as_IN an_DT occasional_JJ consultant_NN ;_:
        Jean-_NNP Louis_NNP Vincent_NNP is_VBZ a_DT consultant_NN to_TO Eli_NNP Lilly_NNP and_CC
        Company_NN ;_: and_CC William_NNP L_NNP Macias_NNP ,_, David_NNP E_NNP Joyce_NNP ,_, Mark_NNP D_NNP
        Williams_NNP ,_, and_CC Joan_NNP Bailey_NNP are_VBP employees_NNS of_IN Eli_NNP Lilly_NNP and_CC
        Company_NN ._.
      
      
        Abbreviations_NNP
        APACHE_NNP =_SYM Acute_NNP Physiology_NNP and_CC Chornic_NNP Health_NNP Evaluation_NNP ;_:
        CI_NNP =_SYM confidence_NN interval_NN ;_: ICH_NNP =_SYM intracranial_NN
        hemorrhage_NN ._.
      
    
  
